Stereotactic Body Radiotherapy for Kidney Cancer
(AQuOS-II Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to treat kidney cancer that cannot be surgically removed, using stereotactic body radiation therapy (SBRT). SBRT targets high doses of radiation on the cancer while sparing surrounding healthy tissue. The trial includes individuals with a primary kidney tumor larger than 3 cm, who cannot or choose not to undergo surgery, and have no cancer spread to other parts of the body. Participants must understand English or have assistance from a translator. As an unphased trial, this study offers a unique opportunity to contribute to innovative research in kidney cancer treatment.
What prior data suggests that stereotactic body radiation therapy is safe for treating kidney cancer?
Research has shown that stereotactic body radiation therapy (SBRT) is generally safe for treating kidney cancer. Studies have found that most patients tolerate SBRT well, experiencing only a small decrease in kidney function over two years. This suggests the treatment is manageable for many individuals.
Additionally, data from several studies indicate a low rate of serious side effects. Most patients do not experience severe problems after receiving SBRT. Other studies have used the treatment at doses similar to those planned here, with good safety results.
Overall, the evidence suggests that SBRT is a safe option for individuals with kidney cancer who cannot undergo surgery.12345Why are researchers excited about this trial?
Stereotactic Body Radiotherapy (SBRT) is unique because it offers a precise, high-dose radiation treatment for kidney cancer, specifically for patients who are medically inoperable. Unlike traditional radiation therapies that often require multiple weeks of treatment, SBRT delivers targeted radiation in just five sessions, minimizing damage to surrounding healthy tissues. Researchers are excited about SBRT because it has the potential to be as effective as surgery, with less risk and recovery time, making it a promising option for patients who cannot undergo surgery.
What evidence suggests that SBRT might be an effective treatment for kidney cancer?
Research has shown that stereotactic body radiotherapy (SBRT) effectively treats renal cell carcinoma (RCC), a type of kidney cancer. A review of studies found that SBRT excels at controlling cancer in the treated area. One study showed that 92% of patients survived for five years due to this treatment. During the same period, about 63.6% of patients experienced no cancer growth or spread. SBRT is also safe in the long term, with some patients experiencing only a small decrease in kidney function. This trial will evaluate SBRT for medically inoperable RCC, offering a promising treatment option for those who cannot undergo surgery.35678
Who Is on the Research Team?
William Chu, MD, FRCPC
Principal Investigator
Sunnybrook Health Sciences Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive stereotactic body radiotherapy (SBRT) with 35-45 Gy in five fractions (7-9 Gy/day) for inoperable RCC
Follow-up
Participants are monitored for safety, toxicity, and quality of life post-treatment
What Are the Treatments Tested in This Trial?
Interventions
- SBRT
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
35-45 Gy in five fractions (7-9 Gy/day)
SBRT is already approved in United States, European Union, Canada, Japan for the following indications:
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
- Spinal tumors
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
- Spinal tumors
- Bone metastases
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
- Spinal tumors
- Prostate cancer
- Lung cancer
- Liver cancer
- Pancreatic cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sunnybrook Health Sciences Centre
Lead Sponsor
Health Sciences North
Collaborator
Juravinski Cancer Center
Collaborator
St. Joseph's Healthcare Hamilton
Collaborator
The Ottawa Hospital
Collaborator
Grand River Regional Cancer Centre
Collaborator
British Columbia Cancer Agency
Collaborator
London Health Sciences Centre
Collaborator
Durham Regional Cancer Centre
Collaborator
Citations
Stereotactic Body Radiotherapy (SBRT) for the Treatment of ...
The results of the meta-analysis show that SBRT for localised renal cell carcinoma is highly effective in controlling local diseases and has low ...
Articles 5-year outcomes after stereotactic ablative body ...
SABR is effective and safe in the long term for patients with primary renal cell carcinoma. Single-fraction SABR might yield less local failure than ...
3.
ascopost.com
ascopost.com/news/november-2022/5-year-outcomes-with-stereotactic-ablative-body-radiotherapy-for-primary-renal-cell-carcinoma/5-Year Outcomes With Stereotactic Ablative Body ...
The 5-year estimates were 92.0% (95% CI = 85.2%β95.8%) for cancer-specific survival and 63.6% (95% CI = 55.6%β70.6%) for progression-free ...
Stereotactic Body Radiation Therapy for Renal Tumors
Kidney-directed SBRT results in modest clinical renal function loss up to 2 years following SBRT, based on evaluable patients in our study. Technical advances ...
5.
dailynews.ascopubs.org
dailynews.ascopubs.org/do/stereotactic-ablative-radiotherapy-metastatic-renal-cell-carcinoma-disease-modifyingIs Stereotactic Ablative Radiotherapy for Metastatic Renal ...
SABR has been shown to improve outcomes including overall survival (OS) for patients with oligometastatic cancers.
5-year outcomes after stereotactic ablative body ...
The primary aim of this study was to report on long-term efficacy and safety of SABR for localised renal cell carcinoma. Methods. This study was ...
Safety and Efficacy of Stereotactic Ablative Radiation Therapy ...
Conclusions. SAbR demonstrated excellent LC of metastatic renal cell carcinoma with a favorable safety profile when an adequate dose and coverage were applied.
Safety and Efficacy of Stereotactic Ablative Radiation ...
The findings suggest that our last dose level of 48 Gy in 4 12-Gy fractions can be considered safe, and it will be used for our subsequent phase 2 study.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.